Share your email to get news and updates!

Recent News

tellus and xontogeny logos2

Tellus Therapeutics Secures Seed Financing to Develop the First Treatment for Newborns with White Matter Brain Injury

DURHAM, N.C, May 12, 2021 –(BUSINESS WIRE)– Tellus Therapeutics, Inc., a biopharmaceutical company developing TT-20 as a treatment for white matter injury (WMI) and myelin repair in premature babies, today announced a seed investment from Xontogeny, LLC to advance their lead program through IND-enabling work.

section_contact

Tellus Therapeutics Awarded NINDS SBIR Funding for Development of TT-20 for Treatment of Neonatal Brain Injury

DURHAM, NC, UNITED STATES, December 7, 2020 — Tellus Therapeutics today announced the award of a Phase 1 NINDS SBIR grant of $696,000 to fund further preclinical development of TT-20.

Tellus_Baby

Tellus Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations

DURHAM, NORTH CAROLINA, October 21, 2020 — Tellus Therapeutics today announced that the U.S. FDA granted Orphan Drug and Rare Pediatric Drug designations for Neonatal Brain Injury Program TT-20.

SAB members

Tellus Therapeutics Announces Appointments to Scientific Advisory Board

DURHAM, NORTH CAROLINA, UNITED STATES, October 5, 2020 — Tellus Therapeutics today announced the appointment of Drs. Terrie Inder and Chi Hornik to the Scientific Advisory Board (SAB).

Portrait of newborn baby and hand inside incubator

Tellus Therapeutics – Traction in 2020

March 11th, 2020

Tellus Therapeutics is on target for a productive 2020 and is gaining traction towards its mission of developing treatments for unmet needs in newborns.

From L to R: Ed Field of BioLabs NC, Dr. Eric Benner,
Dr. Tarun Saxena of Duke CTSI Accelerator,
and Dr. Barry Myers.

First Ever Golden Ticket Awarded to Dr. Eric Benner

December 10, 2019

Duke Clinical & Translational Science Institute and BioLabs North Carolina have awarded the first ever Duke Golden Ticket to Dr. Eric Benner, Assistant Professor of Pediatrics in the Duke School of Medicine, and co-founder of Tellus Therapeutics.

MassChallengeAward

MassChallenge Startup Competition Winner Uses Breast Milk to Fight Cerebral Palsy

Andy Rosen, Boston Globe Staff – October 24, 2019

A North Carolina startup that uses molecules from breast milk to help prevent cerebral palsy took home a $100,000 grant Thursday night, the top prize in the annual awards program carried out by MassChallenge, a nonprofit accelerator program for promising businesses.

SEBIO_190211-14-18

Tellus Therapeutics Wins Early Stage Company Shootout

SEBIO – December 4, 2018

An A-List Group Of Investors And Companies Attended The 20th Anniversary Southeast BIO Investor & Partnering Forum (SEBIO) On November 13-14th At The Loews Hotel In Atlanta.